SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending as traders discuss its low market cap, real-world partnerships with Vodafone and Heathrow, and integration with Polkadot; some community members believe $AVT is undervalued and poised for a breakout. Bullish sentiment surrounds the token, with traders closely monitoring volume as a key indicator, while also pointing to the potential of its appchain model. Some are speculating about a potential pump with a government shutdown and are hoping for new all time highs soon.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to discussions around a potential short squeeze and unusual options activity, indicating bullish sentiment. Community members are debating the company's valuation and future prospects in the quantum computing sector, while also referencing collaborations with companies like NVIDIA. Concerns around cash burn and potential dilution are being weighed against the potential for significant growth and government contracts in the burgeoning quantum computing industry.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending due to its pivot towards quantum computing for cryptocurrency applications, generating excitement around energy-efficient blockchain infrastructure. The community is discussing the potential of LightSolver's laser-based processing units and comparing QCLS to other quantum and crypto-related stocks. Traders are monitoring the stock's threshold list status and anticipating news regarding partnerships and potential contract announcements.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors discuss its price momentum and potential near-term resistance levels, with some eyeing a possible run toward $200. Community members are also weighing in on factors like AI infrastructure deals and potential government shutdowns, considering their impact on the broader market. Additionally, there's chatter around its partnerships with other companies.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community emphasizes its role as a culture coin, promoting freedom and creativity. Discussions highlight its movement within the Solana ecosystem, drawing comparisons to Bitcoin. Community members are sharing links to the Weedcoin website and Dexscreener.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending following the announcement of a strategic partnership with Perplexity, an AI search company, sparking speculation about the implications for Rumble's AI capabilities and potential integration with platforms like Truth Social.  The community is actively discussing the high short interest in RUM, with some believing a short squeeze could be imminent. Many are also highlighting Rumble's ties to crypto, Tether's ownership stake, and the potential for government cloud contracts as possible catalysts.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt ($BKKT) is trending due to a potent combination of crypto market tailwinds and strategic restructuring, including the sale of its loyalty business, fueling speculation of a potential short squeeze. The community is closely watching for news of partnerships and expansion, with many eyeing a run toward previous highs. Bullish sentiment is amplified by the appointment of Mike Alfred to the board, with discussion centering around potential price targets and the company's future in digital assets.

A multi-agent AI platform dissecting human nature’s first principles through iterative survival challenges and data-driven insights. Core dev has access to one of the founding partners of Two Sigma Ventures - the VC company of one of the biggest hedge funds in the world. Plans to raise seed round and scale after building organic foundation. Project devs are from academia space and are trying to bridge the gap between crypto and academia.

CortexZero

CortexZero is gaining attention, with the community highlighting its potential for a breakout and emphasizing the ease of access through Phantom Wallet. Discussions suggest buyers are actively accumulating, anticipating a significant move, with some viewing it as a hidden gem within the crypto space. The community speculates about a potential connection to AI.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid a flurry of activity in the quantum computing sector, including major acquisitions and significant funding rounds for competitors. Community members are actively discussing the potential impact of these developments on QBTS, along with its existing partnerships and recent successes in applying quantum computing to real-world problems. Bullish sentiment is fueled by the belief that QBTS is undervalued compared to peers and poised for significant growth as quantum technology gains wider adoption.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, fueled by high short interest and unusual options activity. Investors are also optimistic about the company's AI-driven drug discovery platform and potential catalysts. Discussions also highlight the company's connection to NVDA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why GSK (GSK) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Emma Walmsley’s decision to step down as chief executive officer of GSK Plc brings to a close a nearly nine-year tenure, leaving the FTSE 100 with just nine female CEOs.Walmsley will pass the baton to Luke Miels, GSK’s chief commercial officer, on Jan. 1 as it tries to refresh its product pipeline and counter an anticipated expiry of patent protection on its bestselling HIV medicine dolutegravir in 2028.Since taking the top job in 2017, Walmsley has led the company through the Covid-19 pandemic and overseen the spinoff of its consumer health unit into Haleon Plc, as well as doubling the group’s spending on research and development, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/walmsley-s-gsk-exit-leaves-ftse-100-female-ceo-tally-stagnating">report</a>.She also bet big on cancer and respiratory medicines through a series of acquisitions, even as some investors questioned the company’s sluggish share performance and activist fund Elliott Management called for change.“2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership,” Walmsley said in a statement.Her tenure has drawn both admiration and criticism as she was the first woman to lead a global pharmaceutical giant, modernized GSK’s operations, and guided it through turbulent markets, but the company’s stock still fell about 11% under her leadership, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/c-suite/gsk-names-luke-miels-to-succeed-ceo-emma-walmsley-17264317">noted</a>.Her successor, Luke Miels, joined GSK from AstraZeneca in 2017 and is widely seen as instrumental in building the company’s specialty medicines business, particularly in oncology and respiratory treatments.GSK is targeting annual sales of over £40 billion ($53.6 billion) by 2031, compared with £31.4 billion last year. Miels now faces the challenge of proving GSK can hit that goal and restore investor confidence in its drug pipeline and vaccines business.On Stocktwits, retail sentiment for GSK was ‘bullish’ amid ‘normal’ message volume.One user questioned whether Walmsley’s exit would meaningfully change GSK’s long-term prospects, noting that both she and former CEO Andrew Witty had delivered “weak returns” and left the company lagging behind other major drugmakers.&nbsp;The user added that they were uncertain about whether to sell their position but hoped the new leadership could help revive the stock.<stembedurl>https://stocktwits.com/SellHoldBuy/message/630362186</stembedurl><a href="https://stocktwits.com/symbol/GSK">GSK’s U.S.-listed stock</a> has risen 25.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Emma Walmsley, CEO of GSK plc arrives for a reception held for UK and EU businesses at Downing Street on May 19, 2025 in London, England.  (Photo by Peter Nicholls/Getty Images)

GSK’s First Female CEO Steps Down After Nearly A Decade — Retail Hopes New Leadership Can Revive Lagging Stock

Emma Walmsley’s departure comes as GSK works to strengthen its drug pipeline and offset the upcoming loss of patent protection on its top-selling HIV drug, dolutegravir.

Equity

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Here's Why GSK (GSK) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSK Glaxosmithkline plc - ADR